Thermo Fisher Scientific Inc. (TMO)
NYSE: TMO · Real-Time Price · USD
580.37
-4.78 (-0.82%)
At close: Dec 2, 2025, 4:00 PM EST
580.36
-0.01 (0.00%)
After-hours: Dec 2, 2025, 7:53 PM EST
Thermo Fisher Revenue
Thermo Fisher had revenue of $11.12B in the quarter ending September 27, 2025, with 4.94% growth. This brings the company's revenue in the last twelve months to $43.74B, up 3.22% year-over-year. In the year 2024, Thermo Fisher had annual revenue of $42.88B with 0.05% growth.
Revenue (ttm)
$43.74B
Revenue Growth
+3.22%
P/S Ratio
5.07
Revenue / Employee
$349,888
Employees
125,000
Market Cap
218.05B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 42.88B | 22.00M | 0.05% |
| Dec 31, 2023 | 42.86B | -2.06B | -4.58% |
| Dec 31, 2022 | 44.92B | 5.70B | 14.55% |
| Dec 31, 2021 | 39.21B | 6.99B | 21.71% |
| Dec 31, 2020 | 32.22B | 6.68B | 26.14% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
TMO News
- 3 hours ago - Thermo Fisher Scientific Deepens Investment in Asia's Biopharma Ecosystem with Expansion of Bioprocess Design Centers - Business Wire
- 15 hours ago - Top 15 High-Growth Dividend Stocks For December 2025 - Seeking Alpha
- 7 days ago - Thermo Fisher Scientific Prices Offering of Euro-Denominated Senior Notes - Business Wire
- 12 days ago - Thermo Fisher Scientific's Oncomine Dx Target Test Receives FDA Approval as a Companion Diagnostic to Identify Patients Eligible for Newest Targeted Therapy for Non-Small Cell Lung Cancer - Business Wire
- 13 days ago - Thermo Fisher Scientific Launches Industry-First, Multi-Parameter Molecular Assay for Rapid Beverage Quality Testing* - Business Wire
- 14 days ago - Thermo Fisher Scientific Opens East Coast Collaboration Center at BioLabs for Advanced Therapeutics to Help Accelerate Cell and Gene Therapy Development - Business Wire
- 15 days ago - Thermo Fisher Scientific Launches CorEvitas Clinical Registry in Myasthenia Gravis, a Rare Autoimmune Disorder - Business Wire
- 18 days ago - Artisan Value Fund Q3 2025 Top Contributors And Detractors - Seeking Alpha